CoChat

Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial☆

Open access
Wu, X.H., Zhu, J.Q., Yin, R.T., Yang, J.X., Liu, J.H., Wang, J., Wu, L.Y., Liu, Z.L., Gao, Y.N., Wang, D.B., Lou, G., Yang, H.Y., Zhou, Q., Kong, B.H., Huang, Y., Chen, L.P., Li, G.L., An, R.F., Wang, K., Zhang, Y., Yan, X.J., Lu, X., Lu, W.G., Hao, M., Wang, L., Cui, H., Chen, Q.H., Abulizi, G., Huang, X.H., Tian, X.F., Wen, H., Zhang, C., Hou, J.M., Mirza, M.R. · 2021 · Annals of Oncology
Cited by 200

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Background This study evaluated maintenance treatment with niraparib, a potent inhibitor of poly(ADP-ribose) polymerase 1/2, in patients with platinum-sensitive recurrent ovarian cancer. Patients and methods In this phase III, double-blind, placebo-controlled study conducted at 30 centers in China, adults with platinum-sensitive recurrent ovarian cancer who had responded to their most recent platinum-containing chemotherapy were randomized 2 : 1 to receive oral niraparib (300 mg/day) or matched placebo until disease progression or unacceptable toxicity (NCT03705156). Following a protocol amendment, patients with a bodyweight <77 kg or a platelet count <150 × 10 3 /μl received 200 mg/day, and all other patients 300 mg/day, as an individualized starting dose (ISD). Randomization was carried out by an interactive web response system and stratified by BRCA mutation, time to recurrence following penultimate chemotherapy, and response to most recent chemotherapy. The primary endpoint was progression-free survival (PFS) assessed by blinded independent central review. Results Between 26 September 2017 and 2 February 2019, 265 patients were randomized to receive niraparib ( n = 177) or placebo ( n = 88); 249 patients received an ISD (300 mg, n = 14; 200 mg, n = 235) as per protocol. In the intention-to-treat population, median PFS was significantly longer for patients receiving niraparib versus placebo: 18.3 [95% confidence interval (CI), 10.9-not evaluable] versus 5.4 (95% CI, 3.7-5.7) months [hazard ratio (HR) = 0.32; 95% CI, 0.23-0.45; P < 0.0001], and a similar PFS benefit was observed in patients receiving an ISD, regardless of BRCA mutation status. Grade ≥3 treatment-emergent adverse events occurred in 50.8% and 19.3% of patients who received niraparib and placebo, respectively; the most common events were neutrophil count decreased (20.3% versus 8.0%) and anemia (14.7% versus 2.3%). Conclusions Niraparib maintenance treatment reduced the risk of disease progression or death by 68% and prolonged PFS compared to placebo in patients with platinum-sensitive recurrent ovarian cancer. Individualized niraparib dosing is effective and safe and should be considered standard practice in this setting.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.annonc.2020.12.018

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 200

Metadata

Authors
Wu, X. H., Zhu, J. Q., Yin, R. T., Yang, J. X., Liu, J. H., Wang, J., Wu, L. Y., Liu, Z. L., Gao, Y. N., Wang, D. B., Lou, G., Yang, H. Y., Zhou, Q., Kong, B. H., Huang, Y., Chen, L. P., Li, G. L., An, R. F., Wang, K., Zhang, Y., Yan, X. J., Lu, X., Lu, W. G., Hao, M., Wang, L., Cui, H., Chen, Q. H., Abulizi, G., Huang, X. H., Tian, X. F., Wen, H., Zhang, C., Hou, J. M., & Mirza, M. R.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2021-04
Volume
32
Issue
4
Pages
512-521
ISSN
0923-7534 (ISSN-L)
OpenAlex
W3120953566
Cited by
200
References
1
FWCI
11.50
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial☆. https://app.cochat.ai/papers/10.1016/j.annonc.2020.12.018
The paper
Wu, X. H., Zhu, J. Q., Yin, R. T., Yang, J. X., Liu, J. H., Wang, J., Wu, L. Y., Liu, Z. L., Gao, Y. N., Wang, D. B., Lou, G., Yang, H. Y., Zhou, Q., Kong, B. H., Huang, Y., Chen, L. P., Li, G. L., An, R. F., Wang, K., . . . Mirza, M. R. (2021). Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial☆. Annals of Oncology. https://doi.org/10.1016/j.annonc.2020.12.018

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.